GW Pharmaceuticals plc GWPH, -2.09% said early Thursday that the Food and Drug Administration will review a new drug application for its cannabis-derived drug epidiolex for seizures associated with two rare types of childhood epilepsy. The application was accepted for priority review, a special ...
read more here
Delivered by @can_nab_is
No comments:
Post a Comment